Physician profile
Michael E Steele
NPI 1427187673
$2,649.74
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.33 · 2022: $518 · 2023: $1,369 · 2024: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $645.48 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $297.19 | 2022-2024 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $259.45 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $217.31 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $157.17 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $152.80 | 2023-2024 | Farxiga, Flumist Quadrivalent |
| Jazz Pharmaceuticals INC. | $140.35 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $111.60 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $89.39 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $79.60 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $70.77 | 2022-2023 | |
| Astellas Pharma US INC | $65.42 | 2022-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.74 | 2022 | |
| Seqirus USA INC | $50.12 | 2022-2024 | Fluad, Flucelvax, Fluad Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $33.59 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $30.51 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.12 | 2022-2024 | Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.75 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.46 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $19.23 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $18.99 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $16.51 | 2024 | Voquezna |
| Alkermes, INC. | $15.11 | 2022 | |
| Halozyme INC | $14.57 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.22 | 2022 | |
| Amgen INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.